Weekend Therapy

Weekend therapy, also called proactive or maintenance therapy, is a way of using anti-inflammatory creams to stop flares instead of only treating them. Once a flare of Atopic Dermatitis has been brought under control (usually after a 2–4 week stabilisation phase), the parent keeps applying a topical corticosteroid (TCS) to the spots that usually flare, on two consecutive days each week (hence “weekend”), even when the skin looks clear. The idea is that skin which looks healed still has low-grade inflammation underneath, and a small regular dose keeps it quiet. The same approach works with Topical Calcineurin Inhibitors (TCIs), which are applied twice weekly on non-consecutive days (for example Monday and Thursday nights) per the National Eczema Society. Daily Emollient Therapy continues alongside.

Weekend Therapy [prevents] Atopic Dermatitis Weekend Therapy [part-of] Topical Corticosteroids Topical Calcineurin Inhibitors [part-of] Weekend Therapy Emollient Therapy [relates] Weekend Therapy

Evidence. The 2022 Cochrane review of TCS strategies (Lax et al., CD013356) compared weekend therapy with no TCS or reactive (flare-only) use in 7 trials (1,149 people, mostly moderate to severe eczema). Flare-ups fell from about 576 to 248 per 1,000 (clinician-reported relapse NNT 3, 95% CI 2.6–4.0); one patient-reported trial (n=343) gave NNT 2.5. Certainty was judged moderate. An earlier meta-analysis by Schmitt et al. (Br J Dermatol 2011) pooled 8 vehicle-controlled RCTs: proactive fluticasone propionate (4 trials) cut the risk of a flare to RR 0.46 (95% CI 0.38–0.55), and proactive Tacrolimus (3 trials) to RR 0.78 (0.60–1.00). That indirect comparison suggested twice-weekly potent TCS may prevent flares better than tacrolimus, but the authors asked for head-to-head trials. In an accompanying editorial, Hywel Williams put it as roughly 2 patients treated with fluticasone versus 4 with tacrolimus to prevent one extra flare (unverified). Neither review had many toddlers in it.

Cochrane [supports] Weekend Therapy Tacrolimus [prevents] Atopic Dermatitis

Guidelines. NICE CG57 (children under 12) suggests weekend therapy for children who have 2–3 flares a month: TCS on two consecutive days a week to prevent flares, with treatment reviewed within 3–6 months. The American Academy of Dermatology also supports proactive TCS for patients with frequent flares (AFP summary of Cochrane 2022). For TCIs, the UK labelling and the National Eczema Society describe twice-weekly maintenance after up to 6 weeks of flare treatment, with Protopic maintenance shown effective over one year. NICE CG57 does not specifically recommend proactive TCI use in under-12s.

NICE CG57 [supports] Weekend Therapy American Academy of Dermatology [supports] Weekend Therapy

Toddler safety. The prevention trials in Cochrane 2022 reported no skin thinning (Skin Atrophy) among 1,050 participants, and the Axon 2021 umbrella review (BMJ Open) found no evidence of harm from weekend or as-needed TCS. Long-term data are thin, though: the prevention trials all lasted under 6 months (Cochrane 2022). One RCT found reversible biochemical HPA Axis Suppression in 2 of 44 children on potent weekend therapy, which is why toddlers usually get mild or moderate potencies. Using the Fingertip Unit to measure doses and a written plan of which sites to treat help keep weekly use low. Proactive TCI use avoids skin thinning entirely, which makes it attractive for the face and eyelids, but tacrolimus 0.03% is licensed only from age 2 (see Topical Calcineurin Inhibitors).

Weekend Therapy [relates] HPA Axis Suppression Weekend Therapy [relates] Skin Atrophy Fingertip Unit [relates] Weekend Therapy

Conflict: [Axon et al., BMJ Open 2021] and [Cochrane, Lax 2022] found no evidence of harm from weekend TCS. [Ahuja & Lio, Pediatric Dermatology 2025] report paediatric Topical Steroid Withdrawal cases with use patterns down to twice-weekly. Unresolved — add to open_questions.

What parents report. Parental fear of steroids is common: the review cited in Steroid Phobia found non-adherence of 49% in steroid-phobic groups vs 14% in others. Weekend therapy asks parents to put steroid on skin that already looks clear, so that fear is a likely barrier. This round did not collect parent reports specific to weekend therapy (no evidence: anecdotal claims made).

Steroid Phobia [opposes] Weekend Therapy

Connections

• Topical Corticosteroids — maintenance strategy using TCS, source: Cochrane 2022; NICE CG57
• Topical Calcineurin Inhibitors — twice-weekly TCI maintenance alternative, source: National Eczema Society; Schmitt 2011
• Tacrolimus — proactive tacrolimus RR 0.78 for flares vs vehicle, source: Schmitt 2011
• Cochrane — Lax 2022 review, weekend therapy NNT≈3, source: CD013356
• NICE CG57 — recommends for 2–3 flares/month, review in 3–6 months, source: NICE CG57
• American Academy of Dermatology — endorses proactive TCS, source: AFP 2023
• HPA Axis Suppression — 2/44 children on potent weekend TCS, source: Axon 2021
• Skin Atrophy — none seen in prevention trials, source: Cochrane 2022
• Topical Steroid Withdrawal — disputed risk at twice-weekly use, source: Ahuja & Lio 2025
• Atopic Dermatitis — prevents flares, source: Cochrane 2022
• Treatment Outcomes Comparison — flare prevention is Track B’s clearest advantage, source: Cochrane 2022
• AAD Pediatric Guideline 2026 — strong rec for intermittent low–medium TCS (≤3×/week) or proactive TCI maintenance, source: JAAD 2026